Evidence map›Paper›PMID 25086069›Full record

ArticleMolecular cancer research : MCR2014

Restoration of compact Golgi morphology in advanced prostate cancer enhances susceptibility to galectin-1-induced apoptosis by modifying mucin O-glycan synthesis.

Armen Petrosyan, Melissa S Holzapfel, David E Muirhead, Pi-Wan Cheng

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 86 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Armen PetrosyanNebraska Western Iowa Health Care System, Veteran Affairs Research Service, Omaha, Nebraska. Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska.
Melissa S HolzapfelDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
David E MuirheadDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska.
Pi-Wan ChengNebraska Western Iowa Health Care System, Veteran Affairs Research Service, Omaha, Nebraska. Department of Biochemistry and Molecular Biology, College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska. pcheng@unmc.edu.
University of Nebraska Medical Center · US

Funding

Alcohol effect on Golgi morphology and functionK01AA022979 · NIAAA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PETROSYAN, ARMEN · 2014 to 2018
$544k
Control of Mucin Glycan Branching in Membrane-bound and Secreted MucinsR21HL097238 · NHLBI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI CHENG, PI-WAN · 2009 to 2010
$385k
Glycosyltransferase Golgi Retention MechanismI01BX000985 · VA · OMAHA VA MEDICAL CENTER · PI CHENG, PI-WAN · 2011 to 2015
–
BLRD VA I01 BX000985NHLBI NIH HHS 1R21HL097238NHLBI NIH HHS R21 HL097238NIAAA NIH HHS K01 AA022979
6 · The paper itself

Abstract

unlabelledProstate cancer progression is associated with upregulation of sialyl-T antigen produced by β-galactoside α-2,3-sialyltransferase-1 (ST3Gal1) but not with core 2-associated polylactosamine despite expression of core 2 N-acetylglucosaminyltransferase-L (C2GnT-L/GCNT1). This property allows androgen-refractory prostate cancer cells to evade galectin-1 (LGALS1)-induced apoptosis, but the mechanism is not known. We have recently reported that Golgi targeting of glycosyltransferases is mediated by golgins: giantin (GOLGB1) for C2GnT-M (GCNT3) and GM130 (GOLGA2)-GRASP65 (GORASP1) or GM130-giantin for core 1 synthase. Here, we show that for Golgi targeting, C2GnT-L also uses giantin exclusively whereas ST3Gal1 uses either giantin or GM130-GRASP65. In addition, the compact Golgi morphology is detected in both androgen-sensitive prostate cancer and normal prostate cells, but fragmented Golgi and mislocalization of C2GnT-L are found in androgen-refractory cells as well as primary prostate tumors (Gleason grade 2-4). Furthermore, failure of giantin monomers to be phosphorylated and dimerized prevents Golgi from forming compact morphology and C2GnT-L from targeting the Golgi. On the other hand, ST3Gal1 reaches the Golgi by an alternate site, GM130-GRASP65. Interestingly, inhibition or knockdown of non-muscle myosin IIA (MYH9) motor protein frees up Rab6a GTPase to promote phosphorylation of giantin by polo-like kinase 3 (PLK3), which is followed by dimerization of giantin assisted by protein disulfide isomerase A3 (PDIA3), and restoration of compact Golgi morphology and targeting of C2GnT-L. Finally, the Golgi relocation of C2GnT-L in androgen-refractory cells results in their increased susceptibility to galectin-1-induced apoptosis by replacing sialyl-T antigen with polylactosamine. IMPLICATIONS: This study demonstrates the importance of Golgi morphology and regulation of glycosylation and provides insight into how the Golgi influences cancer progression and metastasis.

Indexed as

ApoptosisAutoantigensbeta-Galactoside alpha-2,3-SialyltransferaseCell Line, TumorDimerizationGalectin 1GlycosylationGolgi ApparatusGolgi Matrix ProteinsHumansMaleMembrane ProteinsMucinsN-AcetylglucosaminyltransferasesPhosphorylationProstatic NeoplasmsAutoantigensbeta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-acetylglucosaminyl transferasebeta-Galactoside alpha-2,3-SialyltransferaseGalectin 1Golgi Matrix ProteinsGolgin subfamily A member 2GORASP1 protein, humanLGALS1 protein, humanmacrogolginMembrane ProteinsMucinsN-AcetylglucosaminyltransferasesSialyltransferasesST3GAL1 protein, human

Identifiers

PMID25086069
PMCPMC4272641
OpenAlexW2049247159

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.